Search

Your search keyword '"O’Byrne, Ken"' showing total 590 results
Start Over Author "O’Byrne, Ken"
590 results on '"O’Byrne, Ken"'

1. A signal-seeking phase 2 study of Trastuzumab emtansine in tumours harbouring HER2 amplification or mutation

Author

Thavaneswaran, Subotheni, Lin, Frank, Grady, John P., Espinoza, David, Huang, Min Li, Chinchen, Sarah, Sebastian, Lucille, Kansara, Maya, Mersiades, Tony, Lee, Chee Khoon, Desai, Jayesh, Grimison, Peter, Brown, Michael, Millward, Michael, Harrup, Rosemary, O’Byrne, Ken, Nagrial, Adnan, Craft, Paul, Simes, John, Joshua, Anthony M., and Thomas, David M.

Published
2024
Full Text
View/download PDF

4. Durvalumab, Tremelimumab, and Platinum Chemotherapy in EGFR Mutation–Positive NSCLC: An Open-Label Phase 2 Trial (ILLUMINATE)

Author

Lee, Chee Khoon, Liao, Bin-Chi, Subramaniam, Shalini, Chiu, Chao-Hua, Mersiades, Antony J., Ho, Chao-Chi, Brown, Chris, Lai, Chun-Liang, Hughes, Brett G.M., Yang, Tsung-Ying, O’Byrne, Ken, Luo, Yung-Hung, Yip, Sonia, Ho, Ching-Liang, Bray, Victoria, Su, Wu-Chou, Moore, Melissa, Feng, Wei-Lien, Bai, Ya-Ying, Ford, Kate, Cummins, Michelle M., Stockler, Martin R., Solomon, Benjamin J., John, Thomas, and Chih-Hsin Yang, James

Published
2025
Full Text
View/download PDF

6. Spatial Transcriptomic Approaches for Understanding the Tumor Microenvironment (TME)

Author

Rad, Habib Sadeghi, Shiravand, Yavar, Radfar, Payar, Ladwa, Rahul, Warkiani, Majid Ebrahimi, O’Byrne, Ken, Kulasinghe, Arutha, Rezaei, Nima, Series Editor, Ahmed, Atif A., Editorial Board Member, Aguiar, Rodrigo, Editorial Board Member, Ambrosio, Maria R., Editorial Board Member, Artac, Mehmet, Editorial Board Member, Augustine, Tanya N., Editorial Board Member, Bambauer, Rolf, Editorial Board Member, Bhat, Ajaz Ahmad, Editorial Board Member, Bertolaccini, Luca, Editorial Board Member, Bianchini, Chiara, Editorial Board Member, Cavic, Milena, Editorial Board Member, Chakrabarti, Sakti, Editorial Board Member, Cho, William C. S., Editorial Board Member, Czarnecka, Anna M., Editorial Board Member, Domingues, Cátia, Editorial Board Member, Eşkazan, A. Emre, Editorial Board Member, Fares, Jawad, Editorial Board Member, Fonseca Alves, Carlos E., Editorial Board Member, Fru, Pascaline, Editorial Board Member, Da Gama Duarte, Jessica, Editorial Board Member, García, Mónica C., Editorial Board Member, Gener, Melissa A.H., Editorial Board Member, Estrada Guadarrama, José Antonio, Editorial Board Member, Hargadon, Kristian M., Editorial Board Member, Holvoet, Paul, Editorial Board Member, Jurisic, Vladimir, Editorial Board Member, Kabir, Yearul, Editorial Board Member, Katsila, Theodora, Editorial Board Member, Kleeff, Jorg, Editorial Board Member, Liang, Chao, Editorial Board Member, Tan, Mei Lan, Editorial Board Member, Li, Weijie, Editorial Board Member, Prado López, Sonia, Editorial Board Member, Macha, Muzafar A., Editorial Board Member, Malara, Natalia, Editorial Board Member, Orhan, Adile, Editorial Board Member, Prado-Garcia, Heriberto, Editorial Board Member, Pérez-Velázquez, Judith, Editorial Board Member, Rashed, Wafaa M., Editorial Board Member, Sanguedolce, Francesca, Editorial Board Member, Sorrentino, Rosalinda, Editorial Board Member, Shubina, Irina Zh., Editorial Board Member, de Araujo, Heloisa Sobreiro Selistre, Editorial Board Member, Torres-Suárez, Ana Isabel, Editorial Board Member, Włodarczyk, Jakub, Editorial Board Member, Yeong, Joe Poh Sheng, Editorial Board Member, Toscano, Marta A., Editorial Board Member, Wong, Tak-Wah, Editorial Board Member, Yin, Jun, Editorial Board Member, and Yu, Bin, Editorial Board Member

Published
2023
Full Text
View/download PDF

9. Spatial resolution of the head and neck cancer tumor microenvironment to identify tumor and stromal features associated with therapy response.

Author

Berrell, Naomi, Monkman, James, Donovan, Meg, Blick, Tony, O'Byrne, Ken, Ladwa, Rahul, Tan, Chin Wee, and Kulasinghe, Arutha

Subjects
HEAD & neck cancer, TREATMENT effectiveness, TUMOR microenvironment, COMPLEMENT activation, NECK tumors
Abstract

Head and neck cancer (HNC) is the seventh most common cancer globally, resulting in 440 000 deaths per year. While there have been advancements in chemoradiotherapy and surgery, relapse occurs in more than half of HNCs, and these patients have a median survival of 10 months and a 2‐year survival of < 20%. Only a subset of patients displays durable benefits from immunotherapies in metastatic and recurrent HNC, making it critical to understand the tumor microenvironment (TME) underpinning therapy responses in HNC. To recognize biological differences within the TME that may be predictive of immunotherapy response, we applied cutting‐edge geospatial whole‐transcriptome profiling (NanoString GeoMx Digital Spatial Profiler) and spatial proteomics profiling (Akoya PhenoCycler‐Fusion) on a tumor microarray consisting of 25 cores from 12 patients that included 4 immunotherapy‐unresponsive (8 cores) and 2 immunotherapy‐responsive patients (5 cores), as well as 6 immunotherapy naïve patients (12 cores). Through high‐plex, regional‐based transcriptomic mapping of the tumor and TME, pathways involved with the complement system and hypoxia were identified to be differentially expressed in patients who went on to experience a poor immunotherapy response. Single‐cell, targeted proteomic analysis found that immune cell infiltration of the cancer cell mass and interactions of CD8 T cells with tumor and other immune cells were associated with positive immunotherapy response. The relative abundance of specific tumor phenotypes and their interactions with various immune cells was identified to be different between response groups. This study demonstrates how spatial transcriptomics and proteomics can resolve novel alterations in the TME of HNC that may contribute to therapy sensitivity and resistance. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

12. Whole transcriptome profiling of placental pathobiology in SARS‐CoV‐2 pregnancies identifies placental dysfunction signatures

Author

Stylianou, Nataly, primary, Sebina, Ismail, additional, Matigian, Nicholas, additional, Monkman, James, additional, Doehler, Hadeel, additional, Röhl, Joan, additional, Allenby, Mark, additional, Nam, Andy, additional, Pan, Liuliu, additional, Rockstroh, Anja, additional, Sadeghirad, Habib, additional, Chung, Kimberly, additional, Sobanski, Thais, additional, O'Byrne, Ken, additional, Almeida, Ana Clara Simoes Florido, additional, Rebutini, Patricia Zadorosnei, additional, Machado‐Souza, Cleber, additional, Stonoga, Emanuele Therezinha Schueda, additional, Warkiani, Majid E, additional, Salomon, Carlos, additional, Short, Kirsty, additional, McClements, Lana, additional, de Noronha, Lucia, additional, Huang, Ruby, additional, Belz, Gabrielle T, additional, Souza‐Fonseca‐Guimaraes, Fernando, additional, Clifton, Vicki, additional, and Kulasinghe, Arutha, additional

Published
2024
Full Text
View/download PDF

13. Spatial proteomic profiling of tumor and stromal compartments in non‐small‐cell lung cancer identifies signatures associated with overall survival.

Author

Yaghoubi Naei, Vahid, Monkman, James, Sadeghirad, Habib, Mehdi, Ahmed, Blick, Tony, Mullally, William, O'Byrne, Ken, Warkiani, Majid Ebrahimi, and Kulasinghe, Arutha

Subjects
NON-small-cell lung carcinoma, OVERALL survival, TUMOR proteins, PROTEOMICS, LUNG cancer
Abstract

Objectives: Non‐small‐cell lung carcinoma (NSCLC) is the most prevalent and lethal form of lung cancer. The need for biomarker‐informed stratification of targeted therapies has underpinned the need to uncover the underlying properties of the tumor microenvironment (TME) through high‐plex quantitative assays. Methods: In this study, we profiled resected NSCLC tissues from 102 patients by targeted spatial proteomics of 78 proteins across tumor, immune activation, immune cell typing, immune‐oncology, drug targets, cell death and PI3K/AKT modules to identify the tumor and stromal signatures associated with overall survival (OS). Results: Survival analysis revealed that stromal CD56 (HR = 0.384, P = 0.06) and tumoral TIM3 (HR = 0.703, P = 0.05) were associated with better survival in univariate Cox models. In contrast, after adjusting for stage, BCLXL (HR = 2.093, P = 0.02) and cleaved caspase 9 (HR = 1.575, P = 0.1) negatively influenced survival. Delta testing indicated the protective effect of TIM‐3 (HR = 0.614, P = 0.04) on OS. In multivariate analysis, CD56 (HR = 0.172, P = 0.001) was associated with better survival in the stroma, while B7.H3 (HR = 1.72, P = 0.008) was linked to poorer survival in the tumor. Conclusions: Deciphering the TME using high‐plex spatially resolved methods is giving us new insights into compartmentalised tumor and stromal protein signatures associated with clinical endpoints in NSCLC. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

18. Mapping the Spatial Proteome of Head and Neck Tumors: Key Immune Mediators and Metabolic Determinants in the Tumor Microenvironment

Author

Jhaveri, Niyati, primary, Ben Cheikh, Bassem, additional, Nikulina, Nadezhda, additional, Ma, Ning, additional, Klymyshyn, Dmytro, additional, DeRosa, James, additional, Mihani, Ritu, additional, Pratapa, Aditya, additional, Kassim, Yasmin, additional, Bommakanti, Sidharth, additional, Shang, Olive, additional, Berry, Shannon, additional, Ihley, Nicholas, additional, McLane, Michael, additional, He, Yan, additional, Zheng, Yi, additional, Monkman, James, additional, Cooper, Caroline, additional, O'Byrne, Ken, additional, Anand, Bhaskar, additional, Prater, Michael, additional, Basu, Subham, additional, Hughes, Brett G.M., additional, Kulasinghe, Arutha, additional, and Braubach, Oliver, additional

Published
2023
Full Text
View/download PDF

20. Metabolomics at the tumor microenvironment interface: Decoding cellular conversations.

Author

Berrell, Naomi, Sadeghirad, Habib, Blick, Tony, Bidgood, Charles, Leggatt, Graham R., O'Byrne, Ken, and Kulasinghe, Arutha

Subjects
TUMOR microenvironment, DRUG resistance in cancer cells, METABOLOMICS, TUMOR growth, BIOLOGY
Abstract

Cancer heterogeneity remains a significant challenge for effective cancer treatments. Altered energetics is one of the hallmarks of cancer and influences tumor growth and drug resistance. Studies have shown that heterogeneity exists within the metabolic profile of tumors, and personalized‐combination therapy with relevant metabolic interventions could improve patient response. Metabolomic studies are identifying novel biomarkers and therapeutic targets that have improved treatment response. The spatial location of elements in the tumor microenvironment are becoming increasingly important for understanding disease progression. The evolution of spatial metabolomics analysis now allows scientists to deeply understand how metabolite distribution contributes to cancer biology. Recently, these techniques have spatially resolved metabolite distribution to a subcellular level. It has been proposed that metabolite mapping could improve patient outcomes by improving precision medicine, enabling earlier diagnosis and intraoperatively identifying tumor margins. This review will discuss how altered metabolic pathways contribute to cancer progression and drug resistance and will explore the current capabilities of spatial metabolomics technologies and how these could be integrated into clinical practice to improve patient outcomes. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

21. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial

Author

Park, Keunchil, Tan, Eng-Huat, O'Byrne, Ken, Zhang, Li, Boyer, Michael, Mok, Tony, Hirsh, Vera, Yang, James Chih-Hsin, Lee, Ki Hyeong, Lu, Shun, Shi, Yuankai, Kim, Sang-We, Laskin, Janessa, Kim, Dong-Wan, Arvis, Catherine Dubos, Kölbeck, Karl, Laurie, Scott A, Tsai, Chun-Ming, Shahidi, Mehdi, Kim, Miyoung, Massey, Dan, Zazulina, Victoria, and Paz-Ares, Luis

Published
2016
Full Text
View/download PDF

22. IFI27 transcription is an early predictor for COVID-19 outcomes, a multi-cohort observational study

Author

Shojaei, Maryam, Shamshirian, Amir, Monkman, James, Grice, Laura, Tran, Minh, Tan, Chin Wee, Teo, Siok Min, Rodrigues Rossi, Gustavo, McCulloch, Timothy R., Nalos, Marek, Raei, Maedeh, Razavi, Alireza, Ghasemian, Roya, Gheibi, Mobina, Roozbeh, Fatemeh, Sly, Peter D., Spann, Kirsten M., Chew, Keng Yih, Zhu, Yanshan, Xia, Yao, Wells, Timothy J., Senegaglia, Alexandra Cristina, Kuniyoshi, Carmen Lúcia, Franck, Claudio Luciano, dos Santos, Anna Flavia Ribeiro, Noronha, Lucia de, Motamen, Sepideh, Valadan, Reza, Amjadi, Omolbanin, Gogna, Rajan, Madan, Esha, Alizadeh-Navaei, Reza, Lamperti, Liliana, Zuñiga, Felipe, Nova-Lamperti, Estefania, Labarca, Gonzalo, Knippenberg, Ben, Herwanto, Velma, Wang, Ya, Phu, Amy, Chew, Tracy, Kwan, Timothy, Kim, Karan, Teoh, Sally, Pelaia, Tiana M., Kuan, Win Sen, Jee, Yvette, Iredell, Jon, O’Byrne, Ken, Fraser, John F., Davis, Melissa J., Belz, Gabrielle T., Warkiani, Majid E., Gallo, Carlos Salomon, Souza-Fonseca-Guimaraes, Fernando, Nguyen, Quan, Mclean, Anthony, Kulasinghe, Arutha, Short, Kirsty R., Tang, Benjamin, Shojaei, Maryam, Shamshirian, Amir, Monkman, James, Grice, Laura, Tran, Minh, Tan, Chin Wee, Teo, Siok Min, Rodrigues Rossi, Gustavo, McCulloch, Timothy R., Nalos, Marek, Raei, Maedeh, Razavi, Alireza, Ghasemian, Roya, Gheibi, Mobina, Roozbeh, Fatemeh, Sly, Peter D., Spann, Kirsten M., Chew, Keng Yih, Zhu, Yanshan, Xia, Yao, Wells, Timothy J., Senegaglia, Alexandra Cristina, Kuniyoshi, Carmen Lúcia, Franck, Claudio Luciano, dos Santos, Anna Flavia Ribeiro, Noronha, Lucia de, Motamen, Sepideh, Valadan, Reza, Amjadi, Omolbanin, Gogna, Rajan, Madan, Esha, Alizadeh-Navaei, Reza, Lamperti, Liliana, Zuñiga, Felipe, Nova-Lamperti, Estefania, Labarca, Gonzalo, Knippenberg, Ben, Herwanto, Velma, Wang, Ya, Phu, Amy, Chew, Tracy, Kwan, Timothy, Kim, Karan, Teoh, Sally, Pelaia, Tiana M., Kuan, Win Sen, Jee, Yvette, Iredell, Jon, O’Byrne, Ken, Fraser, John F., Davis, Melissa J., Belz, Gabrielle T., Warkiani, Majid E., Gallo, Carlos Salomon, Souza-Fonseca-Guimaraes, Fernando, Nguyen, Quan, Mclean, Anthony, Kulasinghe, Arutha, Short, Kirsty R., and Tang, Benjamin

Abstract

Purpose: Robust biomarkers that predict disease outcomes amongst COVID-19 patients are necessary for both patient triage and resource prioritisation. Numerous candidate biomarkers have been proposed for COVID-19. However, at present, there is no consensus on the best diagnostic approach to predict outcomes in infected patients. Moreover, it is not clear whether such tools would apply to other potentially pandemic pathogens and therefore of use as stockpile for future pandemic preparedness. Methods: We conducted a multi-cohort observational study to investigate the biology and the prognostic role of interferon alpha-inducible protein 27 (IFI27) in COVID-19 patients. Results: We show that IFI27 is expressed in the respiratory tract of COVID-19 patients and elevated IFI27 expression in the lower respiratory tract is associated with the presence of a high viral load. We further demonstrate that the systemic host response, as measured by blood IFI27 expression, is associated with COVID-19 infection. For clinical outcome prediction (e.g., respiratory failure), IFI27 expression displays a high sensitivity (0.95) and specificity (0.83), outperforming other known predictors of COVID-19 outcomes. Furthermore, IFI27 is upregulated in the blood of infected patients in response to other respiratory viruses. For example, in the pandemic H1N1/09 influenza virus infection, IFI27-like genes were highly upregulated in the blood samples of severely infected patients. Conclusion: These data suggest that prognostic biomarkers targeting the family of IFI27 genes could potentially supplement conventional diagnostic tools in future virus pandemics, independent of whether such pandemics are caused by a coronavirus, an influenza virus or another as yet-to-be discovered respiratory virus.

Published
2023

24. Liquid Biopsy Snapshots of Key Phosphoproteomic Pathways in Lung Cancer Patients for Diagnosis and Therapy Monitoring

Author

Ahmed, Mostak, primary, Wuethrich, Alain, additional, Constantin, Nicolas, additional, Shanmugasundaram, Karthik Balaji, additional, Mainwaring, Paul, additional, Kulasinghe, Arutha, additional, O’Leary, Connor, additional, O’Byrne, Ken, additional, Sina, Abu Ali Ibn, additional, Carrascosa, Laura G., additional, and Trau, Matt, additional

Published
2023
Full Text
View/download PDF

26. Abstract CT007: Phase 2-3 trial of pegargiminase plus chemotherapy versus placebo plus chemotherapy in patients with non-epithelioid pleural mesothelioma

Author

Szlosarek, Peter W., primary, Creelan, Ben, additional, Sarkodie, Thomas, additional, Nolan, Luke, additional, Taylor, Paul, additional, Olevsky, Olga, additional, Grosso, Federica, additional, Cortinovis, Diego, additional, Chitnis, Meenali, additional, Roy, Amy, additional, Gilligan, David, additional, Kindler, Hedy, additional, Papadatos-Pastos, Dionysis, additional, Ceresoli, Giovanni L., additional, Mansfield, Aaron, additional, Tsao, Anne, additional, O’Byrne, Ken, additional, Nowak, Anna K., additional, Steele, Jeremy, additional, Sheaff, Michael, additional, Johnston, Amanda, additional, Bomalaski, John, additional, Zauderer, Marjorie, additional, and Fennell, Dean A., additional

Published
2023
Full Text
View/download PDF

28. Abstract 4626: Spatial profiling of the tumor microenvironment in head and neck cancer identifies immune checkpoints and proteins involved in cell death signaling biomarkers of immunotherapy response

Author

Sadeghirad, Habib, primary, Liu, Ning, additional, Monkman, James, additional, Tan, Chin Wee, additional, Cooper, Caroline, additional, Caldera, Jeni, additional, Church, Sarah, additional, Schneider, Fabian, additional, Mansfield, James Robert, additional, O'Byrne, Ken, additional, Davis, Melissa, additional, Hughes, Brett, additional, and Kulasinghe, Arutha, additional

Published
2023
Full Text
View/download PDF

32. Compartmentalized spatial profiling of the tumor microenvironment in head and neck squamous cell carcinoma identifies immune checkpoint molecules and tumor necrosis factor receptor superfamily members as biomarkers of response to immunotherapy

Author

Sadeghirad, Habib, primary, Liu, Ning, additional, Monkman, James, additional, Ma, Ning, additional, Cheikh, Bassem Ben, additional, Jhaveri, Niyati, additional, Tan, Chin Wee, additional, Warkiani, Majid Ebrahimi, additional, Adams, Mark N., additional, Nguyen, Quan, additional, Ladwa, Rahul, additional, Braubach, Oliver, additional, O’Byrne, Ken, additional, Davis, Melissa, additional, Hughes, Brett G. M., additional, and Kulasinghe, Arutha, additional

Published
2023
Full Text
View/download PDF

33. Supplementary Figure 7 from Ran Is a Potential Therapeutic Target for Cancer Cells with Molecular Changes Associated with Activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK Pathways

Author

Yuen, Hiu-Fung, primary, Chan, Ka-Kui, primary, Grills, Claire, primary, Murray, James T., primary, Platt-Higgins, Angela, primary, Eldin, Osama Sharaf, primary, O'Byrne, Ken, primary, Janne, Pasi, primary, Fennell, Dean A., primary, Johnston, Patrick G., primary, Rudland, Philip S., primary, and El-Tanani, Mohamed, primary

Published
2023
Full Text
View/download PDF

34. Supplementary Figure 3 from Ran Is a Potential Therapeutic Target for Cancer Cells with Molecular Changes Associated with Activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK Pathways

Author

Yuen, Hiu-Fung, primary, Chan, Ka-Kui, primary, Grills, Claire, primary, Murray, James T., primary, Platt-Higgins, Angela, primary, Eldin, Osama Sharaf, primary, O'Byrne, Ken, primary, Janne, Pasi, primary, Fennell, Dean A., primary, Johnston, Patrick G., primary, Rudland, Philip S., primary, and El-Tanani, Mohamed, primary

Published
2023
Full Text
View/download PDF

35. Supplementary Methods and Materials from Ran Is a Potential Therapeutic Target for Cancer Cells with Molecular Changes Associated with Activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK Pathways

Author

Yuen, Hiu-Fung, primary, Chan, Ka-Kui, primary, Grills, Claire, primary, Murray, James T., primary, Platt-Higgins, Angela, primary, Eldin, Osama Sharaf, primary, O'Byrne, Ken, primary, Janne, Pasi, primary, Fennell, Dean A., primary, Johnston, Patrick G., primary, Rudland, Philip S., primary, and El-Tanani, Mohamed, primary

Published
2023
Full Text
View/download PDF

36. Supplementary Figure 5 from Ran Is a Potential Therapeutic Target for Cancer Cells with Molecular Changes Associated with Activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK Pathways

Author

Yuen, Hiu-Fung, primary, Chan, Ka-Kui, primary, Grills, Claire, primary, Murray, James T., primary, Platt-Higgins, Angela, primary, Eldin, Osama Sharaf, primary, O'Byrne, Ken, primary, Janne, Pasi, primary, Fennell, Dean A., primary, Johnston, Patrick G., primary, Rudland, Philip S., primary, and El-Tanani, Mohamed, primary

Published
2023
Full Text
View/download PDF

37. Supplementary Figure 8 from Ran Is a Potential Therapeutic Target for Cancer Cells with Molecular Changes Associated with Activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK Pathways

Author

Yuen, Hiu-Fung, primary, Chan, Ka-Kui, primary, Grills, Claire, primary, Murray, James T., primary, Platt-Higgins, Angela, primary, Eldin, Osama Sharaf, primary, O'Byrne, Ken, primary, Janne, Pasi, primary, Fennell, Dean A., primary, Johnston, Patrick G., primary, Rudland, Philip S., primary, and El-Tanani, Mohamed, primary

Published
2023
Full Text
View/download PDF

38. Supplementary Figure 1 from Ran Is a Potential Therapeutic Target for Cancer Cells with Molecular Changes Associated with Activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK Pathways

Author

Yuen, Hiu-Fung, primary, Chan, Ka-Kui, primary, Grills, Claire, primary, Murray, James T., primary, Platt-Higgins, Angela, primary, Eldin, Osama Sharaf, primary, O'Byrne, Ken, primary, Janne, Pasi, primary, Fennell, Dean A., primary, Johnston, Patrick G., primary, Rudland, Philip S., primary, and El-Tanani, Mohamed, primary

Published
2023
Full Text
View/download PDF

39. Supplementary Figure Legends 1-10 from Ran Is a Potential Therapeutic Target for Cancer Cells with Molecular Changes Associated with Activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK Pathways

Author

Yuen, Hiu-Fung, primary, Chan, Ka-Kui, primary, Grills, Claire, primary, Murray, James T., primary, Platt-Higgins, Angela, primary, Eldin, Osama Sharaf, primary, O'Byrne, Ken, primary, Janne, Pasi, primary, Fennell, Dean A., primary, Johnston, Patrick G., primary, Rudland, Philip S., primary, and El-Tanani, Mohamed, primary

Published
2023
Full Text
View/download PDF

40. Supplementary Tables 1-3 from Ran Is a Potential Therapeutic Target for Cancer Cells with Molecular Changes Associated with Activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK Pathways

Author

Yuen, Hiu-Fung, primary, Chan, Ka-Kui, primary, Grills, Claire, primary, Murray, James T., primary, Platt-Higgins, Angela, primary, Eldin, Osama Sharaf, primary, O'Byrne, Ken, primary, Janne, Pasi, primary, Fennell, Dean A., primary, Johnston, Patrick G., primary, Rudland, Philip S., primary, and El-Tanani, Mohamed, primary

Published
2023
Full Text
View/download PDF

41. Supplementary Figure 6 from Ran Is a Potential Therapeutic Target for Cancer Cells with Molecular Changes Associated with Activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK Pathways

Author

Yuen, Hiu-Fung, primary, Chan, Ka-Kui, primary, Grills, Claire, primary, Murray, James T., primary, Platt-Higgins, Angela, primary, Eldin, Osama Sharaf, primary, O'Byrne, Ken, primary, Janne, Pasi, primary, Fennell, Dean A., primary, Johnston, Patrick G., primary, Rudland, Philip S., primary, and El-Tanani, Mohamed, primary

Published
2023
Full Text
View/download PDF

42. Supplementary Figure 2 from Ran Is a Potential Therapeutic Target for Cancer Cells with Molecular Changes Associated with Activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK Pathways

Author

Yuen, Hiu-Fung, primary, Chan, Ka-Kui, primary, Grills, Claire, primary, Murray, James T., primary, Platt-Higgins, Angela, primary, Eldin, Osama Sharaf, primary, O'Byrne, Ken, primary, Janne, Pasi, primary, Fennell, Dean A., primary, Johnston, Patrick G., primary, Rudland, Philip S., primary, and El-Tanani, Mohamed, primary

Published
2023
Full Text
View/download PDF

43. Supplementary Figure 9 from Ran Is a Potential Therapeutic Target for Cancer Cells with Molecular Changes Associated with Activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK Pathways

Author

Yuen, Hiu-Fung, primary, Chan, Ka-Kui, primary, Grills, Claire, primary, Murray, James T., primary, Platt-Higgins, Angela, primary, Eldin, Osama Sharaf, primary, O'Byrne, Ken, primary, Janne, Pasi, primary, Fennell, Dean A., primary, Johnston, Patrick G., primary, Rudland, Philip S., primary, and El-Tanani, Mohamed, primary

Published
2023
Full Text
View/download PDF

44. Supplementary Figure 4 from Ran Is a Potential Therapeutic Target for Cancer Cells with Molecular Changes Associated with Activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK Pathways

Author

Yuen, Hiu-Fung, primary, Chan, Ka-Kui, primary, Grills, Claire, primary, Murray, James T., primary, Platt-Higgins, Angela, primary, Eldin, Osama Sharaf, primary, O'Byrne, Ken, primary, Janne, Pasi, primary, Fennell, Dean A., primary, Johnston, Patrick G., primary, Rudland, Philip S., primary, and El-Tanani, Mohamed, primary

Published
2023
Full Text
View/download PDF

45. 2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer

Author

Eberhardt, W.E.E., De Ruysscher, D., Weder, W., Le Péchoux, C., De Leyn, P., Hoffmann, H., Westeel, V., Stahel, R., Felip, E., Peters, S., Stahel, Rolf, Felip, Enriqueta, Peters, Solange, Kerr, Keith, Besse, Benjamin, Vansteenkiste, Johan, Eberhardt, Wilfried, Edelman, Martin, Mok, Tony, O'Byrne, Ken, Novello, Silvia, Bubendorf, Lukas, Marchetti, Antonio, Baas, Paul, Reck, Martin, Syrigos, Konstantinos, Paz-Ares, Luis, Smit, Egbert F., Meldgaard, Peter, Adjei, Alex, Nicolson, Marianne, Crinó, Lucio, Van Schil, Paul, Senan, Suresh, Faivre-Finn, Corinne, Rocco, Gaetano, Veronesi, Giulia, Douillard, Jean-Yves, Lim, Eric, Dooms, Christophe, Weder, Walter, De Ruysscher, Dirk, Le Pechoux, Cecile, De Leyn, Paul, and Westeel, Virginie

Published
2015
Full Text
View/download PDF

46. Whole transcriptome profiling of placental pathobiology in SARS-CoV-2 pregnancies identifies a preeclampsia-like gene signature

Author

Stylianou, Nataly, primary, Sebina, Ismail, additional, Matigian, Nicholas, additional, Monkman, James, additional, Doehler, Hadeel, additional, Röhl, Joan, additional, Allenby, Mark, additional, Nam, Andy, additional, Pan, Liuliu, additional, Rockstroh, Anja, additional, Sadeghirad, Habib, additional, Chung, Kimberly, additional, Sobanski, Thais, additional, O’Byrne, Ken, additional, Rebutini, Patricia Zadorosnei, additional, Machado-Souza, Cleber, additional, Stonoga, Emanuele Therezinha Schueda, additional, Warkiani, Majid E, additional, Salomon, Carlos, additional, Short, Kirsty, additional, McClements, Lana, additional, de Noronha, Lucia, additional, Huang, Ruby, additional, Belz, Gabrielle T., additional, Souza-Fonseca-Guimaraes, Fernando, additional, Clifton, Vicki, additional, and Kulasinghe, Arutha, additional

Published
2023
Full Text
View/download PDF

47. IFI27 transcription is an early predictor for COVID-19 outcomes, a multi-cohort observational study

Author

Shojaei, Maryam, primary, Shamshirian, Amir, additional, Monkman, James, additional, Grice, Laura, additional, Tran, Minh, additional, Tan, Chin Wee, additional, Teo, Siok Min, additional, Rodrigues Rossi, Gustavo, additional, McCulloch, Timothy R., additional, Nalos, Marek, additional, Raei, Maedeh, additional, Razavi, Alireza, additional, Ghasemian, Roya, additional, Gheibi, Mobina, additional, Roozbeh, Fatemeh, additional, Sly, Peter D., additional, Spann, Kirsten M., additional, Chew, Keng Yih, additional, Zhu, Yanshan, additional, Xia, Yao, additional, Wells, Timothy J., additional, Senegaglia, Alexandra Cristina, additional, Kuniyoshi, Carmen Lúcia, additional, Franck, Claudio Luciano, additional, dos Santos, Anna Flavia Ribeiro, additional, Noronha, Lucia de, additional, Motamen, Sepideh, additional, Valadan, Reza, additional, Amjadi, Omolbanin, additional, Gogna, Rajan, additional, Madan, Esha, additional, Alizadeh-Navaei, Reza, additional, Lamperti, Liliana, additional, Zuñiga, Felipe, additional, Nova-Lamperti, Estefania, additional, Labarca, Gonzalo, additional, Knippenberg, Ben, additional, Herwanto, Velma, additional, Wang, Ya, additional, Phu, Amy, additional, Chew, Tracy, additional, Kwan, Timothy, additional, Kim, Karan, additional, Teoh, Sally, additional, Pelaia, Tiana M., additional, Kuan, Win Sen, additional, Jee, Yvette, additional, Iredell, Jon, additional, O’Byrne, Ken, additional, Fraser, John F., additional, Davis, Melissa J., additional, Belz, Gabrielle T., additional, Warkiani, Majid E., additional, Gallo, Carlos Salomon, additional, Souza-Fonseca-Guimaraes, Fernando, additional, Nguyen, Quan, additional, Mclean, Anthony, additional, Kulasinghe, Arutha, additional, Short, Kirsty R., additional, and Tang, Benjamin, additional

Published
2023
Full Text
View/download PDF

48. Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer

Author

Stahel, Rolf, Felip, Enriqueta, Peters, Solange, Kerr, Keith, Besse, Benjamin, Vansteenkiste, Johan, Eberhardt, Wilfried, Edelman, Martin, Mok, Tony, O'Byrne, Ken, Novello, Silvia, Bubendorf, Lukas, Marchetti, Antonio, Baas, Paul, Reck, Martin, Syrigos, Konstantinos, Paz-Ares, Luis, Smit, Egbert F., Meldgaard, Peter, Adjei, Alex, Nicolson, Marianne, Crinò, Lucio, Van Schil, Paul, Senan, Suresh, Faivre-Finn, Corinne, Rocco, Gaetano, Veronesi, Giulia, Douillard, Jean-Yves, Lim, Eric, Dooms, Christophe, Weder, Walter, De Ruysscher, Dirk, Le Pechoux, Cecile, De Leyn, Paul, Westeel, Virginie, Kerr, K.M., Bubendorf, L., Edelman, M.J., Marchetti, A., Mok, T., Novello, S., O'Byrne, K., Stahel, R., Peters, S., and Felip, E.

Published
2014
Full Text
View/download PDF

49. 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up

Author

Stahel, Rolf, Felip, Enriqueta, Peters, Solange, Kerr, Keith, Besse, Benjamin, Vansteenkiste, Johan, Eberhardt, Wilfried, Edelman, Martin, Mok, Tony, O'Byrne, Ken, Novello, Silvia, Bubendorf, Lukas, Marchetti, Antonio, Baas, Paul, Reck, Martin, Syrigos, Konstantinos, Paz-Ares, Luis, Smit, Egbert F., Meldgaard, Peter, Adjei, Alex, Nicolson, Marianne, Crinò, Lucio, Van Schil, Paul, Senan, Suresh, Faivre-Finn, Corinne, Rocco, Gaetano, Veronesi, Giulia, Douillard, Jean-Yves, Lim, Eric, Dooms, Christophe, Weder, Walter, De Ruysscher, Dirk, Le Pechoux, Cecile, De Leyn, Paul, Westeel, Virginie, Vansteenkiste, J., Crinò, L., Dooms, C., Douillard, J.Y., Faivre-Finn, C., Lim, E., Rocco, G., Senan, S., Van Schil, P., Veronesi, G., Stahel, R., Peters, S., and Felip, E.

Published
2014
Full Text
View/download PDF

50. 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease

Author

Stahel, Rolf, Felip, Enriqueta, Peters, Solange, Kerr, Keith, Besse, Benjamin, Vansteenkiste, Johan, Eberhardt, Wilfried, Edelman, Martin, Mok, Tony, O'Byrne, Ken, Novello, Silvia, Bubendorf, Lukas, Marchetti, Antonio, Baas, Paul, Reck, Martin, Syrigos, Konstantinos, Paz-Ares, Luis, Smit, Egbert F., Meldgaard, Peter, Adjei, Alex, Nicolson, Marianne, Crinò, Lucio, Van Schil, Paul, Senan, Suresh, Faivre-Finn, Corinne, Rocco, Gaetano, Veronesi, Giulia, Douillard, Jean-Yves, Lim, Eric, Dooms, Christophe, Weder, Walter, De Ruysscher, Dirk, Le Pechoux, Cecile, De Leyn, Paul, Westeel, Virginie, Besse, B., Adjei, A., Baas, P., Meldgaard, P., Nicolson, M., Paz-Ares, L., Reck, M., Smit, E.F., Syrigos, K., Stahel, R., Felip, E., and Peters, S.

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results